Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2012

Open Access 01-12-2012 | Research

Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma

Authors: Zhao-lei Zeng, Wen-jing Wu, Jing Yang, Zhen-jie Tang, Dong-liang Chen, Miao-zhen Qiu, Hui-yan Luo, Zhi-qiang Wang, Ying Jin, De-shen Wang, Rui-hua Xu

Published in: Journal of Translational Medicine | Issue 1/2012

Login to get access

Abstract

Background

Melanoma antigen D1 (MAGED1) is a member of the type II melanoma antigen (MAGE) family. The down-regulation of MAGED1 expression has been shown in breast carcinoma cell lines and in glioma stem cells and may play an important role in apoptosis and anti-tumorigenesis. However, there is no report on its clinical role in colorectal cancer (CRC).

Methods

We examined the expression of MAGED1 by qPCR in colorectal cancer tissues and their adjacent non-tumorous tissues taken from 6 cases and performed Western blotting and IHC analyses. In addition, we analyzed MAGED1 expression in 285 clinicopathologically characterized colorectal cancer patients.

Results

MAGED1 expression was significantly down-regulated in colorectal cancer tissues compared with adjacent non-tumorous tissues and was associated with clinical stage (p < 0.001), T classification (p = 0.001), N classification (p < 0.001), M classification (p < 0.001) and pathologic differentiation (p = 0.002). Patients with lower MAGED1 expression had a shorter survival time than those with higher MAGED1 expression. Univariate and multivariate analyses indicated that MAGED1 expression was an independent prognostic factors (p < 0.001).

Conclusions

MAGED1 may serve as a novel prognostic biomarker of human colorectal cancer.
Appendix
Available only for authorised users
Literature
1.
van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, Knuth A, Boon T: A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science. 1991, 254: 1643-1647. 10.1126/science.1840703.CrossRefPubMed
2.
De Plaen E, Arden K, Traversari C, Gaforio JJ, Szikora JP, De Smet C, Brasseur F, van der Bruggen P, Lethe B, Lurquin C: Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics. 1994, 40: 360-369. 10.1007/BF01246677.CrossRefPubMed
3.
Lurquin C, De Smet C, Brasseur F, Muscatelli F, Martelange V, De Plaen E, Brasseur R, Monaco AP, Boon T: Two members of the human MAGEB gene family located in Xp21.3 are expressed in tumors of various histological origins. Genomics. 1997, 46: 397-408. 10.1006/geno.1997.5052.CrossRefPubMed
4.
Lucas S, De Smet C, Arden KC, Viars CS, Lethe B, Lurquin C, Boon T: Identification of a new MAGE gene with tumor-specific expression by representational difference analysis. Cancer Res. 1998, 58: 743-752.PubMed
5.
Wang X, Gao X, Xu Y: MAGED1: molecular insights and clinical implications. Ann Med. 2011, 43: 347-355. 10.3109/07853890.2011.573806.CrossRefPubMed
6.
Lucas S, Brasseur F, Boon T: A new MAGE gene with ubiquitous expression does not code for known MAGE antigens recognized by T cells. Cancer Res. 1999, 59: 4100-4103.PubMed
7.
Shiras A, Sengupta A, Shepal V: Cloning and tissue-specific gene expression studies with Dlxin-1, a newly identified transcriptional activator. Mol Cell Biol Res Commun. 2001, 4: 313-319. 10.1006/mcbr.2001.0298.CrossRefPubMed
8.
Masuda Y, Sasaki A, Shibuya H, Ueno N, Ikeda K, Watanabe K: Dlxin-1, a novel protein that binds Dlx5 and regulates its transcriptional function. J Biol Chem. 2001, 276: 5331-5338. 10.1074/jbc.M008590200.CrossRefPubMed
9.
Sasaki A, Masuda Y, Iwai K, Ikeda K, Watanabe K: A ring finger protein praja1 regulates Dlx5-dependent transcription through its ubiquitin ligase activity for the Dlx/Msx-interacting MAGE/Necdin family protein, Dlxin-1. J Biol Chem. 2002, 277: 22541-22546. 10.1074/jbc.M109728200.CrossRefPubMed
10.
Salehi AH, Xanthoudakis S, Barker PA: NRAGE, a p75 neurotrophin receptor-interacting protein, induces caspase activation and cell death through a JNK-dependent mitochondrial pathway. J Biol Chem. 2002, 277: 48043-48050. 10.1074/jbc.M205324200.CrossRefPubMed
11.
Kendall SE, Battelli C, Irwin S, Mitchell JG, Glackin CA, Verdi JM: NRAGE mediates p38 activation and neural progenitor apoptosis via the bone morphogenetic protein signaling cascade. Mol Cell Biol. 2005, 25: 7711-7724. 10.1128/MCB.25.17.7711-7724.2005.CrossRefPubMedPubMedCentral
12.
Wen CJ, Xue B, Qin WX, Yu M, Zhang MY, Zhao DH, Gao X, Gu JR, Li CJ: hNRAGE, a human neurotrophin receptor interacting MAGE homologue, regulates p53 transcriptional activity and inhibits cell proliferation. FEBS Lett. 2004, 564: 171-176. 10.1016/S0014-5793(04)00353-9.CrossRefPubMed
13.
Tian XX, Rai D, Li J, Zou C, Bai Y, Wazer D, Band V, Gao Q: BRCA2 suppresses cell proliferation via stabilizing MAGE-D1. Cancer Res. 2005, 65: 4747-4753. 10.1158/0008-5472.CAN-05-0018.CrossRefPubMedPubMedCentral
14.
Reddy EM, Chettiar ST, Kaur N, Ganeshkumar R, Shepal V, Shanbhag NC, Shiras A: Dlxin-1, a member of MAGE family, inhibits cell proliferation, invasion and tumorigenicity of glioma stem cells. Cancer Gene Ther. 2011, 18: 206-218. 10.1038/cgt.2010.71.CrossRefPubMed
15.
Chung FY, Cheng TL, Chang HJ, Chiu HH, Huang MY, Chang MS, Chen CC, Yang MJ, Wang JY, Lin SR: Differential gene expression profile of MAGE family in taiwanese patients with colorectal cancer. J Surg Oncol. 2010, 102: 148-153. 10.1002/jso.21580.CrossRefPubMed
16.
Teng KY, Qiu MZ, Li ZH, Luo HY, Zeng ZL, Luo RZ, Zhang HZ, Wang ZQ, Li YH, Xu RH: DNA polymerase eta protein expression predicts treatment response and survival of metastatic gastric adenocarcinoma patients treated with oxaliplatin-based chemotherapy. J Transl Med. 2010, 8: 126-10.1186/1479-5876-8-126.CrossRefPubMedPubMedCentral
17.
Li M, Lin YM, Hasegawa S, Shimokawa T, Murata K, Kameyama M, Ishikawa O, Katagiri T, Tsunoda T, Nakamura Y, Furukawa Y: Genes associated with liver metastasis of colon cancer, identified by genome-wide cDNA microarray. Int J Oncol. 2004, 24: 305-312.PubMed
18.
Bertrand M, Huijbers I, Chomez P, De Backer O: Comparative expression analysis of the MAGED1 genes during embryogenesis and brain development. Dev Dyn. 2004, 230: 325-334. 10.1002/dvdy.20026.CrossRefPubMed
19.
Panda S, Hogenesch JB, Kay SA: Circadian rhythms from flies to human. Nature. 2002, 417: 329-335. 10.1038/417329a.CrossRefPubMed
20.
Reppert SM, Weaver DR: Coordination of circadian timing in mammals. Nature. 2002, 418: 935-941. 10.1038/nature00965.CrossRefPubMed
21.
Fu L, Lee CC: The circadian clock: pacemaker and tumour suppressor. Nat Rev Cancer. 2003, 3: 350-361. 10.1038/nrc1072.CrossRefPubMed
22.
Wang X, Tang J, Xing L, Shi G, Ruan H, Gu X, Liu Z, Wu X, Gao X, Xu Y: Interaction of MAGED1 with nuclear receptors affects circadian clock function. EMBO J. 2010, 29: 1389-1400. 10.1038/emboj.2010.34.CrossRefPubMedPubMedCentral
23.
Fu L, Pelicano H, Liu J, Huang P, Lee C: The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell. 2002, 111: 41-50. 10.1016/S0092-8674(02)00961-3.CrossRefPubMed
24.
Oda A, Katayose Y, Yabuuchi S, Yamamoto K, Mizuma M, Shirasou S, Onogawa T, Ohtsuka H, Yoshida H, Hayashi H: Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin. Anticancer Res. 2009, 29: 1201-1209.PubMed
25.
Hua H, Wang Y, Wan C, Liu Y, Zhu B, Wang X, Wang Z, Ding JM: Inhibition of tumorigenesis by intratumoral delivery of the circadian gene mPer2 in C57BL/6 mice. Cancer Gene Ther. 2007, 14: 815-818. 10.1038/sj.cgt.7701061.CrossRefPubMed
26.
Oshima T, Takenoshita S, Akaike M, Kunisaki C, Fujii S, Nozaki A, Numata K, Shiozawa M, Rino Y, Tanaka K: Expression of circadian genes correlates with liver metastasis and outcomes in colorectal cancer. Oncol Rep. 2011, 25: 1439-1446.CrossRefPubMed
27.
Zeng ZL, Wu MW, Sun J, Sun YL, Cai YC, Huang YJ, Xian LJ: Effects of the biological clock gene Bmal1 on tumour growth and anti-cancer drug activity. J Biochem. 2010, 148: 319-326. 10.1093/jb/mvq069.CrossRefPubMed
28.
Hanoun M, Eisele L, Suzuki M, Greally JM, Huttmann A, Aydin S, Scholtysik R, Klein-Hitpass L, Duhrsen U, Durig J: Epigenetic silencing of the circadian clock gene CRY1 is associated with an indolent clinical course in chronic lymphocytic leukemia. PLoS One. 2012, 7: e34347-10.1371/journal.pone.0034347.CrossRefPubMedPubMedCentral
29.
Iurisci I, Filipski E, Sallam H, Harper F, Guettier C, Maire I, Hassan M, Iacobelli S, Levi F: Liver circadian clock, a pharmacologic target of cyclin-dependent kinase inhibitor seliciclib. Chronobiol Int. 2009, 26: 1169-1188.CrossRefPubMed
Metadata
Title
Prognostic relevance of melanoma antigen D1 expression in colorectal carcinoma
Authors
Zhao-lei Zeng
Wen-jing Wu
Jing Yang
Zhen-jie Tang
Dong-liang Chen
Miao-zhen Qiu
Hui-yan Luo
Zhi-qiang Wang
Ying Jin
De-shen Wang
Rui-hua Xu
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2012
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-10-181

Other articles of this Issue 1/2012

Journal of Translational Medicine 1/2012 Go to the issue

Meeting report

Rational design of HIV vaccines and microbicides: report of the EUROPRISE annual conference 2011

Research

Small molecule inhibition of 6-phosphofructo-2-kinase suppresses t cell activation

Methodology

Clinical trial considerations on male contraception and collection of pregnancy information from female partners

Research

Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model

Research

Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens

Review

Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits